ImageneBio Inc
ImageneBio Inc (IMA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IMA · as of Jun 8, 2026
Key Statistics
Explore ImageneBio Inc Data
ima stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 5 · Buy rate: 80.0%
The IMA analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $1.33, representing -76.38% downside from the current price of $5.63.
Competitors & Peers
ima competitorsIMA
ARTV
CNTB
CNTX
IFRX
KLRSStock Performance
Full HistoryAbout ImageneBio Inc
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and in…
what is imagenebio inc · ima stock overview · imagenebio inc company profile · who is imagenebio inc ceo · ima NASDAQ · imagenebio inc headquarters · imagenebio inc business segments
About Stock Overview & Key Data
ImageneBio Inc (IMA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 27, 1998. As of the latest trading session, IMA stock price is $5.63, with a market capitalization of $63.5M. The stock has returned -68.08% over the past 12 months and -18.41% year-to-date.
According to 5 Wall Street analysts, the consensus rating for ImageneBio Inc stock is Buy, with an average 12-month price target of $1.33. In fiscal year 2025, ImageneBio Inc reported revenue of $800000.00 and net income of -$45.3M. For detailed data — including ImageneBio Inc revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, ImageneBio Inc (IMA) stock price is $5.63. The stock is traded on NASDAQ under the ticker symbol IMA. The 52-week range is $3.94 – $18.00.